Intellia NTLA-2001

Brief description of study

To evaluate the efficacy of NTLA-2001, as measured by the composite risk of CV-related mortality and CV events (urgent HF visits and hospitalizations due to HF, MI, arrhythmia, or stroke), compared to placebo Composite endpoint comprising Cardiovascular related mortality and frequency and timing of Cardiovascular events (urgent Heart Failure visits and hospitalizations due to Heart Failure, Myocardial Infraction, arrhythmia, or stroke) - Change from baseline to Month 18 in serum TTR - Change from baseline to Month 18 in KCCQ-OS score - Change from baseline to Month 18 in NT-proBNP - Cardiovascular related mortality, All-cause mortality - Frequency of CV events (urgent Heart Failure visits and hospitalizations due to Heart Failure, Myocardial Infarction, arrhythmia, or stroke)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 854881

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).